Search Results

Published SEATTLE II Results Support Low-Dose Thrombolysis With EkoSonic System for Acute PE

August 24, 2015—Ekos Corporation, a BTG International group company, announced that the results of the SEATTLE II trial were published by Gregory Piazza, MD, et al in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2015;8:1382–1392).

SEATTLE II Supports Treatment of Acute PE With the Ekos EkoSonic System

March 30, 2014—Ekos Corporation (Bothell, WA), a BTG International group company, announced that the results of the SEATTLE II trial were presented at ACC.14: the 63rd annual scientific session of the American College of Cardiology in Washington, DC.

Virtual, Cloud-Based PREVENT-HD Trial Evaluates Rivaroxaban to Prevent Thrombosis in COVID-19 Patients

May 16, 2023—The Feinstein Institutes for Medical Research at Northwell Health, which is based in Manhasset, New York, recently announced findings from the entirely virtual, outpatient, cloud-based PREVENT-HD trial, which the Feinstein Institutes helped to design and implement to understand the efficacy of rivaroxaban.

Thrombolex Bashir Catheter Analyzed for Acute Intermediate-Risk PE Patients in RESCUE

October 24, 2023—Thrombolex, Inc., a Pennsylvania-based medical device company focused on the treatment of arterial and venous thromboembolic diseases, announced the publication of an independent core-lab data analysis of 107 patients with acute intermediate-risk pulmonary embolism (PE) treated with the company’s Bashir endovascular catheter and small doses of recombinant tissue plasminogen activator (r-tPA) at 18 sites in the United States.

OPTALYSE PE Evaluates Ekos System to Treat Bilateral Pulmonary Embolism

May 1, 2018—BTG International announced that results from the OPTALYSE PE trial of the company's EkoSonic endovascular system for the treatment of bilateral pulmonary embolism (PE) were presented at the Society for Cardiovascular Angiography and Interventions scientific sessions, held April 25–28 in San Diego, California.

2-Year ATTRACT Data: Anticoagulation Alone Best for Most DVT; PCDT Benefits Seen in Certain Iliofemoral Patients

March 6, 2017—The much-anticipated 2-year results from the ATTRACT study were presented by Suresh Vedantham, MD, FSIR, on behalf of the trial’s investigators, at the 2017 Society of Interventional Radiology (SIR) Annual Scientific Meeting.